Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Tislelizumab as Consolidation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Next Previous
Search
Trial Profile

A Phase II Trial of Tislelizumab as Consolidation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Tislelizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Results assessing efficacy of neoadjuvant chemoimmunotherapy +/- bevacizumab, guided by the Ki value, followed by hypofractionated radiotherapy, concurrent chemotherapy (hypo-CCRT), and consolidative immunotherapy in unresectalbe stage III NSCLC were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 31 Dec 2023 Planned number of patients changed from 60 to 116, Drugs Docetaxel, Cisplatin, and Anlotinib has been removed from study.
    • 31 Dec 2023 Planned End Date changed from 1 Feb 2024 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top